Start
•
Completion

A randomised, double blind, active placebo-controlled crossover trial to evaluate the short term efficacy of an N-Methyl-D-Aspartate antagonist for patients with treatment resistant depression

CompletedResults publishedRegisteredANZCTR

This randomised, double-blind, active placebo-controlled crossover trial (n=30) investigates the short-term efficacy of ketamine for patients with treatment-resistant depression (TRD).

Details

Randomised, double-blind crossover comparing single IV ketamine (bolus 0.25 mg/kg then infusion 0.25 mg/kg/hr for 45 minutes) with an active remifentanil comparator; 3-week washout between sessions.

Primary outcome assessed with MADRS; ancillary measures include plasma BDNF at 4 hours post-intervention and follow-ups at days 1, 7, 14 and 21 during a 42-day study period.

Topics:Treatment-Resistant Depression (TRD)

Registry

Registry linkACTRN12615000573550